trending Market Intelligence /marketintelligence/en/news-insights/trending/f6jfqjv1v3eihukuhvw4za2 content esgSubNav
In This List

CardioComm seeks US FDA approval for heart rhythm monitor

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


CardioComm seeks US FDA approval for heart rhythm monitor

CardioComm Solutions Inc. filed a 510(k) application with the U.S. Food and Drug Administration, seeking approval for its heart rhythm monitor, HeartCheck.

The device allows the user to do a medical grade electrocardiogram recording by holding the device in the right hand and against the left side of the chest.

The company said the rechargeable and Bluetooth-enabled device will be named HeartCheck Cardi Beat and marketed as the HeartCheck Beat.

Toronto-based CardioComm Solutions develops software and hardware products, as well as core laboratory reading services, related to electrocardiogram and ambulatory arrhythmia monitoring systems.